The role of radiotherapy in extensive-stage small cell lung cancer: insights from treatment failure patterns in the era of immunotherapy
Open Access
- 18 December 2024
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-12
Abstract
The therapeutic advantage of radiotherapy (RT) as an adjunct to first-line immunotherapy and chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC) remains unclear. This study aimed to elucidate the value of RT based on the first failure pattern of ES-SCLC. In this study, we retrospectively analyzed ES-SCLC patients treated with first-line chemotherapy and immune checkpoint inhibitors (ICIs) at Shanghai Chest Hospital from August 2018 to October 2023. Our study recorded the first failure pattern in ES-SCLC, analyzed the main sites of disease progression, explored factors that may affect prognosis and estimated the value of RT in extending patient survival in the immunotherapy era. Key endpoints included the first failure pattern, progression-free survival (PFS) and overall survival (OS). Among 344 patients, 70 (20%) had local failure, 105 (31%) had distant failure, 69 (20%) experienced both types of failure, and 100 (29%) showed no disease progression. Disease progression occurred in 244 patients (71%). They were divided into two groups: 183 without pre-progression RT and 61 with pre-progression RT. In the non-pre-progression RT group, 55 patients (30%) had local failure, 72 patients (39%) had distant failure, and 56 patients (31%) had both. In the pre-progression RT group, 15 patients (25%) had local failure, 33 patients (54%) had distant failure, and 13 patients (21%) had both. Univariate and multivariate analyses identified RT as an independent prognostic factor for improved OS (P < 0.05). Subgroup analysis further confirmed these findings. Pre-progression RT was associated with superior PFS (P < 0.05). The median overall survival (mOS) was 20.1 months (95% confidence interval [CI]: 15.5–24.7 months) in the pre-progression RT group, compared to 13.4 months (95% CI: 13.4–19.2 months) in the non-pre-progression RT group. RT improved OS in these patients, and pre-progression RT improved PFS further. Pre-progression RT shows a trend toward OS benefit.Keywords
Funding Information
- National Natural Science Foundation of China (82373199)
This publication has 23 references indexed in Scilit:
- 1988MO Recruitment discontinuation in TREASURE trial (thoracic radiotherapy with atezolizumab in small cell lung cancer extensive disease) due to unexpected safety dataAnnals of Oncology, 2023
- Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real worldClinical & Experimental Metastasis, 2023
- Patterns of treatment failure for PD-(L)1 refractory extensive-stage small cell lung cancer in continued PD-(L)1 treatmentTranslational Oncology, 2023
- Is consolidative thoracic radiotherapy of extensive-stage small cell lung cancer still beneficial in the era of immunotherapy? A retrospective analysisStrahlentherapie und Onkologie, 2023
- Extensive‐stage small‐cell lung cancer: Current management and future directionsInternational Journal of Cancer, 2022
- Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung CancerJAMA, 2022
- Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIANESMO Open, 2022
- Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extracranial Irradiation for Extensive-Disease Small Cell Lung Cancer (ED SCLC): NRG Oncology RTOG 0937Journal of Thoracic Oncology, 2017
- Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trialThe Lancet, 2015
- Small cell lung cancer: Where do we go from here?Cancer, 2014